THE ABORTION PILL'S EXILE IN OBSCURITY.

The article offers a look into the obscurity of mifepristone, an abortion pill developed by French pharmaceutical firm Roussel Uclaf, since its approval by the U.S. Food and Drug Administration (FDA) in 2000. It attributes the obscurity of the pill to regulatory restrictions known as risk evaluation and mitigation strategy (REMS) that included prescribing. It explores implication of the U.S. Supreme Court's possible overturn of the Roe v. Wade abortion rights ruling on the sale of mifepristone.